Immunotherapy has transformed cancer treatment by harnessing the body’s immune system to fight the disease.
Yet, despite its potential, access to these therapies remains limited—particularly in low- and middle-income countries (LMICs), where cost barriers often prevent eligible patients from receiving life-saving treatments. In this comprehensive whitepaper, explore the current landscape of immuno-oncology and strategies to expand global access to immunotherapy.
Key insights include innovative pricing models, resource pooling, and value-based treatment research, offering pathways for biotech and pharma companies to improve accessibility and patient outcomes in immunotherapy worldwide.
"*" indicates required fields